Is screening for breast cancer cost-effective?

Cancer. 1992 Apr 1;69(7 Suppl):1957-62. doi: 10.1002/1097-0142(19920401)69:7+<1957::aid-cncr2820691716>3.0.co;2-t.

Abstract

As the toll taken by breast cancer continues unabated, screening programs are widely perceived to play a critical role to improve diagnosis and successful treatment. Breast cancer screening programs are increasingly promoted to women; however, the economic implications of mass screening is a subject of much health policy debate. Cost-effectiveness analysis is an economic methodology widely used to inform such decisions, yet there is a dearth of information available on the economic consequences of mass breast cancer screening. The authors evaluated nine breast cancer screening cost-effectiveness studies that are based on computer simulations, observational trial data, or a combination of both. The results of these studies, conducted in the United States and other countries, indicate that the cost-effectiveness of screening for breast cancer generally compares favorably with other expenditures in the health-care field, although screening younger women does not appear to be as favorable. However, there is considerable variability in the methodology used and a need for more comprehensive research in this area.

MeSH terms

  • Adult
  • Breast Neoplasms / prevention & control*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Male
  • Mass Screening / economics*
  • Middle Aged
  • United States